These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 8799651

  • 21. Metabolic syndrome and the menopause.
    Kaaja RJ.
    Menopause Int; 2008 Mar; 14(1):21-5. PubMed ID: 18380957
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
    Chapman MJ, Sposito AC.
    Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
    Nesto R.
    Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The 'thrifty' hypotheses: clinical and epidemiological significance for non-insulin-dependent diabetes mellitus and cardiovascular disease risk factors.
    Chukwuma C, Tuomilehto J.
    J Cardiovasc Risk; 1998 Feb; 5(1):11-23. PubMed ID: 9816551
    [Abstract] [Full Text] [Related]

  • 30. Insulin resistance and its impact on the approach to therapy of type 2 diabetes.
    Laakso M.
    Int J Clin Pract Suppl; 2001 Sep; (121):8-12. PubMed ID: 11594246
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Insulin resistance: from clinical diagnosis to molecular genetics. Implications in diabetes mellitus].
    Jaffiol C, Rouard M, Macari F, Lautier C, Ait el Mkadem S, Méchaly I, Brun JF, Renard E, Cros G, Bringer J, Grigorescu F.
    Bull Acad Natl Med; 1999 Sep; 183(9):1761-75; discussion 1775-7. PubMed ID: 10987057
    [Abstract] [Full Text] [Related]

  • 35. Insulin resistance as an intermediary endpoint.
    Lithell HO.
    Blood Press Suppl; 1997 Sep; 2():108-12. PubMed ID: 9495638
    [Abstract] [Full Text] [Related]

  • 36. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
    Yamagishi S, Matsui T, Sato T, Takeuchi M.
    Med Hypotheses; 2006 Sep; 66(3):609-11. PubMed ID: 16171951
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Negative effects of chronic inflammatory periodontal disease on diabetes mellitus.
    Nishimura F, Kono T, Fujimoto C, Iwamoto Y, Murayama Y.
    J Int Acad Periodontol; 2000 Apr; 2(2):49-55. PubMed ID: 12666961
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.